T2 Biosystms Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.35 million
- Book Value:
- Revenue TTM:
- $17.15 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
T2 Biosystms Inc had its IPO on 2014-08-07 under the ticker symbol TTOO.
The company operates in the Healthcare sector and Diagnostics & Research industry. T2 Biosystms Inc has a staff strength of 158 employees.
Shares of T2 Biosystms Inc opened at $0.1 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of $0.09 - $0.1, and closed at $0.1.
This is a -11.22% slip from the previous day's closing price.
A total volume of 10,410,700 shares were traded at the close of the day’s session.
In the last one week, shares of T2 Biosystms Inc have slipped by -65.33%.
T2 Biosystms Inc's Key Ratios
T2 Biosystms Inc has a market cap of $2.35 million, indicating a price to book ratio of 14.5044 and a price to sales ratio of 0.3967.
In the last 12-months T2 Biosystms Inc’s revenue was $17.15 million with a gross profit of $-24766000 and an EBITDA of $-52858000. The EBITDA ratio measures T2 Biosystms Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, T2 Biosystms Inc’s operating margin was -314.16% while its return on assets stood at -82.36% with a return of equity of -622.14%.
In Q1, T2 Biosystms Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 71.3%.
T2 Biosystms Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-7.69 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into T2 Biosystms Inc’s profitability.
T2 Biosystms Inc stock is trading at a EV to sales ratio of 2.062 and a EV to EBITDA ratio of -0.8719. Its price to sales ratio in the trailing 12-months stood at 0.3967.
T2 Biosystms Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $32.73 million
- Total Liabilities
- $17.83 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
T2 Biosystms Inc ended 2023 with $32.73 million in total assets and $0 in total liabilities. Its intangible assets were valued at $32.73 million while shareholder equity stood at $-49886000.00.
T2 Biosystms Inc ended 2023 with $0 in deferred long-term liabilities, $17.83 million in other current liabilities, 21000.00 in common stock, $-552184000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.12 million and cash and short-term investments were $10.12 million. The company’s total short-term debt was $1,415,000 while long-term debt stood at $50.11 million.
T2 Biosystms Inc’s total current assets stands at $18.93 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.32 million compared to accounts payable of $3.13 million and inventory worth $4.94 million.
In 2023, T2 Biosystms Inc's operating cash flow was $0 while its capital expenditure stood at $120000.
Comparatively, T2 Biosystms Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
T2 Biosystms Inc stock is currently trading at $0.1 per share. It touched a 52-week high of $11 and a 52-week low of $11. Analysts tracking the stock have a 12-month average target price of $0.57.
Its 50-day moving average was $0.36 and 200-day moving average was $2.16 The short ratio stood at 0.89 indicating a short percent outstanding of 0%.
Around 85% of the company’s stock are held by insiders while 697.1% are held by institutions.
Frequently Asked Questions About T2 Biosystms Inc
Similar Industry Stocks (Diagnostics & Research)
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.